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INTRODUCTION
Hepatitis C virus (HCV) is a single-stranded RNA virus that
infects both the liver and lymphoid cells [1,2]. HCV infection
has a strong tendency to evolve to chronicity and often
progresses to cirrhosis and eventually to hepatocellular
carcinoma [3,4]. The mechanisms by which this virus
establishes such a high rate of persistent infection are still
poorly understood. Some evidence suggests that the alter-
ation in the interferon (IFN) system may be involved in the
chronicity of this infection [5]. In addition, the function of
peripheral blood lymphoid cells has been closely related to
viral load [6,7].Treatment with recombinant IFN-a2, which
is the current therapy, leads to sustained viral clearance only
in a small proportion of treated patients [8].
Human IFN-a comprises a family of extracellular signal-
ling cytokines which confer resistance to viral infection
[9–11] and have antiproliferative and immunomodulatory
activities [12,13]. In a previous publication we described
that in patients with chronic hepatitis C, IFN-a gene
expression is downregulated in the liver but upregulated in
peripheral blood mononuclear cells (PBMC) [14]. Since HCV
can infect lymphoid cells [2] and these cells play an
important role in the clearance of viral infection, we decided
to analyse the interferon responsive factors (IRF) and the
expression of specific IFN-a subtypes in PBMC from HCV
infected patients.
IRF-1 and IRF-2 belong to a family of DNA-binding
proteins which regulate interferon genes and interferon-
inducible genes [15,16]. They bind to the same DNA element
where IRF-1 acts as a positive regulator and IRF-2 is as a
negative transcription factor that lacks the transactivation
domain [17]. The increase in the IRF-1/IRF-2 ratio seems to
be a critical event in the transcriptional activation of IFN and
subsequent development of the cellular antiviral response
[18,19].
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interferon regulatory factor; PBMC, peripheral blood mononuclear
cells.
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SUMMARY. Interferon (IFN)-a is a family of antiviral proteins
encoded by different genes. The biological significance of the
existence of various IFN-a subtypes is not clear. We have
investigated the interferon system in chronic hepatitis C
virus (HCV) infection, a disease that responds to interferon-
a2 therapy in only a limited proportion of cases. We ana-
lysed the expression of interferon regulatory factor (IRF)-1,
IRF-2, and IFN-a subtypes in nonstimulated and Sendai
virus-stimulated peripheral blood mononuclear cells (PBMC)
from HCV infected patients and healthy controls. We
observed that the IRF-1 mRNA and IRF-1/IRF-2 ratios were
increased in PBMC from hepatitis C patients with respect to
normal subjects. Sendai virus stimulation of PBMC led to a
significant increase in the levels of IRF-1, IRF-2 and IFN-a
mRNAs and in the production of IFN-a protein with respect
to basal values in healthy controls as well as in patients with
HCV infection. In addition, we found that while natural HCV
infection induced increased IFN-a5 expression in PBMC,
in vitro infection of these cells with Sendai virus caused a
raise in the expression of IFN-a8 in both patients and normal
controls. In summary, our results indicate that virus-
induced activation of the IFN system in human PBMC is
associated with selective expression of individual IFN-a
subtypes, IFN-a5 being the specific subtype induced in PBMC
from patients with chronic HCV infection.
Keywords: hepatitis C virus, interferon regulatory factor,
interferon-a subtypes, peripheral blood mononuclear cells,
Sendai virus.
IFN-a proteins are encoded by a multigene family com-
prising 13 intronless genes which show 78–94% homology
at the nucleotide level [20] and are clustered in human
chromosome 9 [21]. Individual IFN-a genes seem to be dif-
ferentially expressed depending on the stimulus and on the
producer cell type [15,22]. The biological significance of the
large abundance of IFN-a genes is not clear. Although all
IFN-a subtypes bind to a common receptor, several reports
suggest that they show quantitatively distinct patterns of
antiviral, growth inhibitory and immunomodulatory activ-
ities [23–25]. A combination of different IFN-a subtypes
has been found in normal human unstimulated PBMC
[14,26–28] and in Sendai virus-induced human PBMC
[26,27,29]. However the expression of the different IFN-a
subtypes in human viral infections has been poorly studied.
In the present report we demonstrate that the interferon
system is activated in PBMC from HCV infected patients. In
addition we show that while IFN-a5 seems to be induced in
PBMC in HCV infection, IFN-a8 is the subtype produced by
human PBMC in response to Sendai virus.
MATERIALS AND METHODS
Patients
We analysed PBMC samples from 41 patients with chronic
hepatitis C. When diagnosed, chronic hepatitis C patients had
raised serum transaminases for more than 6 months,
positivity for anti-HCV antibodies (ELISA second-generation,
Ortho Diagnostic System, Raritan, NJ, USA), presence of HCV-
RNA by RT-PCR in serum and histological evidence of chronic
hepatitis. Other causes of chronic hepatitis were excluded.
Twelve patients were sustained responders to interferon
treatment (persistent normal serum transaminases and neg-
ative HCV-RNA in serum for at least 10 months after com-
pletion of 1 years IFN treatment) when studied. None of the
patients had received treatment with IFN-a in the 10-month
period prior to the study. Table 1 shows the biochemical,
histological and virological characteristics of the patients.
As controls, a group of 41 healthy volunteers (20 male,
21 female, age range from 24 to 55 years) were studied.
Detection, quantification and genotyping of HCV-RNA
was performed as previously described [30].
Cell culture and stimulation
PBMC (1 · 107) resuspended in 5 mL of RPMI 1640 medium
(Bio-Whittaker, Verviers, Belgium), supplemented with 1% of
fetal calf serum and penicillin-streptomycin (100 U and
100 lg/mL, respectively), were incubated for 6 h at 37 °C
and 5% CO2 with or without 16 haemagglutination units per
mL of Sendai virus. Following induction, PBMC were pelleted,
washed once in 0.9% NaCl and lysed in Ultraspec (Biotecx,
Houston, TX, USA). The samples were stored at )80 °C until
extraction of total RNA, which was performed according to
the methods of Chomczynski and Sacchi [31].
Simultaneously, other aliquots of 5 · 106 PBMC were
cultured for 24 h under the same conditions with and
without Sendai virus. Supernatants of PBMC were collected
and stored at )80 °C until IFN-a protein was determined.
Under these conditions cell viability, tested with Trypan
blue, was 100%.
Analysis of IFN-a mRNA levels and identification
of IFN-a subtypes
Total RNA was extracted from PBMC samples and IFN-a
mRNA levels were determined by semiquantitative RT-PCR
HCV-RNA (+)
(n  29)
HCV-RNA ())
(n  12)
Age range (years) 26–74 24–62
Sex 13 male, 16 female 10 male, 2 female
Serum ALT (IU/L) 62.5  7.4* 13.4  1.2
Serum AST (IU/L) 42.2  5.9 12.3  0.8
GGTP (IU/L) 31.2  4.4 12.4  1.1
Liver histological activity
Total Knodell’s score 9.7  0.6 6.3  0.6
Cirrhosis (n) 5 0
Serum HCV-RNA (copies/mL) 1.6 · 108  0.6 · 108 Non-detected
Viral genotype (n)
1b 25 5**
1a 2 0**
3 2 6**
2 0 1**
* Means  SD. **Pretreatment viral genotype.
Table 1 Biochemical, histological and
virological characteristics of patients
with chronic hepatitis C
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in a Perkin Elmer Gene Amp PCR System 2400 (Perkin
Elmer, Foster City, CA, USA). Before the reverse transcription,
1 lg of total RNA was treated with 1 U of deoxyribonuclease
(DNase I amplification grade, Gibco-BRL, Gaithersburg, MD,
USA) to remove all the contaminating DNA. In all cases
the presence of traces of DNA was excluded by performing
control reactions without reverse transcriptase. RNA was
reverse transcribed (60 min at 37 °C) with 200 U of
M-MuLV reverse transcriptase (Gibco-BRL) in 20 lL volume
of 5 · RT buffer (250 mM Tris-HCl pH 8.3, 375 mM KCl,
15 mM MgCl2) supplemented with 5 mM dithiothreitol (DDT),
0.5 mM deoxynucleoside triphosphate (Boehringer Mann-
heim, Mannheim, Germany), 25 U ribonuclease inhibitor
(Promega Corporation, Madison, WI, USA) and 200 ng
random hexamers (Boehringer Mannheim). After heating
(95 °C, 1 min) and quick-chilling on ice, an aliquot of 6 lL
(0.3 lg) of the cDNA pool was used for PCR amplification in
50 lL of 10 · buffer solution (100 mM Tris-HCl pH 9.3,
500 mM KCl, 1% Triton X-100) containing 0.08 mM dNTP,
3.5 lCi (a-32P)-dCTP (Amersham, Buckinghamshire, UK),
upstream and downstream primers (40 ng each), 1.5 mM
MgCl2 and 2 U of Taq DNA polymerase (Promega Corpora-
tion). Blank reactions with no RNA were performed in all
experiments. As an internal control for each sample, PCR
amplification of a fragment of b-actin cDNA (using 6 lL
aliquot of the cDNA pool) was performed. IFN-a cDNA frag-
ments were amplified by 20 cycles (94 °C, 60 °C and 72 °C,
1 min per step) and b-actin fragments were amplified by 20
cycles (94 °C, 55 °C and 72 °C, 1 min per step) a protocol
that avoided interference of the plateau effect. We used
universal primers designed to amplify all IFN-a subtypes.
Oligonucleotides (5¢–3¢) d(TCCATGAGATGATCCAGCAG) and
d(ATTTCTGCTCTGACAACCTCCC) were the upstream and
downstream primers, respectively, for amplification of 274
base pair (bp) fragment from human IFN-a cDNA [20] that is
located between nucleotides 240–514 [32]. Primers were
designed to obtain the same amplification efficiency for all
IFN-a subtypes. The two primers correspond to the two most
conserved regions among all subtypes. The sequence for
annealing of the downstream primer is identical for all of
them. The annealing sequence of the upstream primer is the
same for subtypes 2, 4, 5, 7, 8, 10, 16, 17 and 21 and it
differs in only one nucleotide in subtypes 1, 14 and 22 (this
change does not occur in the 3¢ end of the primer).
d(TCTACAATGAGCTGCGTGTG) and d(GGTGAGGATCTT-
CATGAGGT) were the primers used for amplification of a
314-bp fragment (nucleotides 1319–2079) from the repor-
ted human b-actin gene sequence [33].
After PCR amplification, 20 lL aliquots of the PCR reac-
tions were electrophoresed in 2% agarose gel stained with
ethidium bromide, and bands were visualized with an UV
lamp. Equal size bands were excised and radioactivities were
determined. Obtained values were corrected with back-
ground radioactivity from blank reactions with no RNA.
Finally, values corresponding to IFN-a mRNA were nor-
malized to those of b-actin mRNA and results were expressed
as cpm ratio of IFN-a to b-actin. b-Actin is used as internal
control because we have previously shown that b-actin
mRNA is constantly expressed in PBMC of healthy controls
and patients with chronic hepatitis C [30].
Validation experiments on PCR assays using known
quantities of total RNA showed linearity of the counts of
amplification bands from 0.125 to 1 lg for IFN-a and
b-actin. Thus 0.3 lg for IFN-a and b-actin, respectively,
were chosen as a suitable amount of total RNA to avoid the
plateau effect. The coefficient of interassay variation for
IFNa/b-actin was 15%. The identity of the PCR product from
IFN-a cDNA amplification was verified by automatic
sequencing (ABI PRISMä 310 Genetic Analyser, Perkin
Elmer).
The identification of IFN-a subtype transcripts was per-
formed by cloning the RT-PCR products using the TOPO TA
cloning kit (Invitrogen, Carlsbad, CA, USA). Clones from
each insert were sequenced in ABI PRISMTM 310 Genetic
Analyser (Perkin Elmer) using the dye Rhodamine termi-
nator cycle sequencing kit (Perkin Elmer).
Analysis of IFN-a protein
To quantify IFN-a protein levels in PBMC supernatants of
unstimulated and Sendai virus-stimulated PBMC, we used
an ELISA (Cytosceenä, Biosource International, Camarillo,
CA, USA) using specific antihuman IFN-a antibodies. The
assay was performed following the instructions of the man-
ufacturers. The sensitivity limit of the assay was 25 pg/mL.
Analysis of IRF-1 and IRF-2 mRNA levels
Estimation of IRF-1 and IRF-2 mRNA levels was carried out
using previously described RT-PCR methodology. Total RNA
from PBMC was reverse-transcribed (0.2 and 0.3 lg for
IRF-1 and IRF-2, respectively) and the cDNA pool was used
for PCR amplification, as above, but using 200 ng for each
IRF-1 and IRF-2 upstream and downstream primers. b-Actin
was also used as an internal control for each sample. IRF-1
and IRF-2 cDNA fragments were amplified by 19 and 28
cycles, respectively (94 °C, 55 °C and 72 °C, 1 min per step),
to avoid the plateau effect. Oligonucleotides d(CTGA-
TACCTTCTCTGATGG) and d(TCCAGGTTCATTGAGTAGG)
were the upstream and downstream primers used to amplify
a 353-bp fragment from human IRF-1 cDNA, that is located
between nucleotides 631–983 [34]. d(TTTTCAGATCC-
CCTGGATGC) and d(TCAGTGGTGACCTCTACAAC) were the
primers used for amplification of 525 bp fragment from
human IRF-2 cDNA that is located between nucleotides
197–721 [35].
Validation experiments of PCR assays using known
quantities of total RNA (from 0 to 1 lg) were carried out,
and 0.3 lg for IRF-1 and 0.2 lg for IRF-2 were chosen as
the suitable amount of total RNA to stay in the linear part of
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the curve. The coefficient of interassay variation for IRF-1/
b-actin and IRF-2/b-actin was 7.5% and 14%, respectively.
The identity of the PCR product from IRF-1 and IRF-2 cDNA
amplification was further verified by enzymatic digestion.
We used EcoO109 I (for IRF-1) and EcoR I (for IRF-2) that
yielded the predicted restriction fragments, while Sac I did
not digest the amplified PCR products (no restriction sites for
this endonuclease are present in the amplified regions).
Statistical analysis
Results of IFN-a, IRF-1 and IRF-2 are given as mean 
standard errors of the mean. Normality was assessed with
the Shapiro–Wilks’ test. Statistical analysis of IFN-a, IRF-1
and IRF-2 levels in PBMC were performed using nonpara-
metric test (Kruskal–Wallis and Mann–Whitney U-tests).
Associations between quantitative variables were studied
with Spearman’s correlation coefficient. IFN-a subtypes
expressed in PBMC, before and after Sendai virus stimula-
tion, were analysed with Wilcoxon test. All P-values were
two-tailed. SPSS 6.0 for Windows was used for the statistical
analysis.
RESULTS
Expression of interferon regulatory factors in PBMC
from normal subjects and patients with present
and past HCV infection
We have previously demonstrated that the values of IFN-a
mRNA in unstimulated PBMC from HCV-RNA positive
patients was higher than healthy controls [14]. To further
analyse the activation of the interferon system in PBMC we
have now determined the level of IRF-1 and IRF-2 gene
expression in healthy subjects, patients with chronic hepa-
titis C and in patients who cleared HCV infection after IFN
therapy. We found that in unstimulated PBMC, IRF-1 mRNA
levels (Fig. 1a) and the IRF-1/IRF-2 ratio (Fig. 1b) were
higher in HCV-RNA positive patients than in healthy con-
trols. Patients with sustained complete virological and bio-
chemical response after IFN therapy showed IRF-1 mRNA
levels (Fig. 1a) and IRF-1/IRF-2 ratio similar to healthy
controls (Fig. 1b). The levels of IRF-2 mRNA were compar-
able in the three groups studied (0.67  0.06; 0.87  0.07
and 0.85  0.1; healthy controls, HCV-RNA (+) patients
and HCV-RNA (–) patients, respectively).
No correlation was observed between IRF-1 or IRF-2 levels
and serum transaminases nor between IRF-1 or IRF-2-
values and liver damage as estimated in liver biopsies by the
Knodell’s score of histological activity. Also no correlation
was found between IRF-1 or IRF-2 mRNA levels and viral
load as determined by competitive PCR in viraemic patients.
Moreover, no differences in IRF-1 or IRF-2 mRNA values
were found in patients infected with different HCV geno-
types.
The effect of Sendai virus stimulation on IFN-a, IRF-1
and IRF-2 gene expression in PBMC from healthy
controls, patients with chronic hepatitis C and patients
who cleared HCV after interferon therapy
Sendai virus stimulation led to a significant increase in the
levels of IRF-1, IRF-2 and IFN-a mRNA in PBMC with
respect to basal values in healthy controls as well as in
patients with present and past HCV infection (Table 2).
Stimulated IRF-1, IRF-2 and IFN-a mRNA levels were similar
in the three groups studied (Table 2).
We also measured IFN-a protein in supernatants from
PBMC with and without Sendai virus stimulation. IFN-a
protein could not be detected in supernatants from unsti-
mulated PBMC in any of the three groups studied. After
Sendai virus stimulation IFN-a protein increased to similar
values in all groups (17 600  2223; 12 616  1572 and
19 348  4766 pg/mL in healthy controls, HCV-RNA
positive and HCV-RNA negative patients, respectively).
Expression of IFN-a subtypes in PBMC
The IFN-a cDNAs generated by RT-PCR were cloned and
sequenced. In unstimulated PBMC, we studied 75 clones
from eight healthy subjects and 83 clones from eight
patients with chronic hepatitis C. We found a broad spec-
trum of IFN-a subtypes in both healthy controls and HCV-
RNA positive patients. IFN-a5, IFN-a1 and IFN-a21 were the
main subtypes, comprising nearly 80% of total IFN-a in
unstimulated PBMC from healthy subjects. In patients with
HCV infection, as compared to normal controls, we found a
significant increase in the expression of IFN-a5 (P < 0.05)
which represented 65% of all sequenced clones (Table 3).
Five patients and five controls were also studied after
Sendai virus stimulation. As shown in Table 4, after Sendai
virus stimulation, a mixture of different IFN-a subtypes were
expressed in both patients and controls. IFN-a1, IFN-a8,
Fig. 1 (a) mRNA levels of IRF-1 and (b) IRF-1/IRF-2 ratio
(as a ratio to b-actin) in unstimulated PBMC from healthy
controls, patients with chronic HCV infection (HCV-RNA
(+)) and patients who cleared HCV after interferon therapy
(HCV-RNA ())).
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IFN-a2 and IFN-a5 were the major subtypes expressed in
healthy controls, comprising 82.8% of total IFN. IFN-a1,
IFN-a8 and IFN-a2 were the major subtypes expressed in
HCV-RNA positive patients, comprising 79% of total IFN.
IFN-a8 was the only IFN-a subtype which increased signifi-
cantly in both, healthy controls (P < 0.05) and HCV-RNA
positive patients (P < 0.05). The expression of IFN-a5 sub-
type decreased significantly after Sendai virus stimulation in
HCV positive patients (P < 0.05). This subtype also tended to
decrease after Sendai virus infection in healthy controls but
in these subjects the differences were not statistically signi-
ficant.
DISCUSSION
Both the activation of the interferon system and the specific
antiviral T-cell immunity, measured in peripheral blood
mononuclear cells, appear to be important in the control of
Table 2 IRF-1, IRF-2 and IFN-a mRNA levels (as a ratio to b-actin) in unstimulated and Sendai virus stimulated peripheral
blood mononuclear cells (PBMC) in healthy controls, in patients with chronic hepatitis C and positive HCV-RNA in serum
(HCV-RNA(+)) and patients who cleared HCV-RNA (HCV-RNA ())) after interferon therapy
IRF-1 IRF-2 IFN-a
Unstimulated
PBMC
Stimulated
PBMC
Unstimulated
PBMC
Stimulated
PBMC
Unstimulated
PBMC
Stimulated
PBMC
Healthy Controls 0.04  0.01a 0.13  0.01* 0.67  0.06 1.16  0.16* Ndb 1.45  0.12*
HCV-RNA (+) 0.08  0.01 0.18  0.01* 0.87  0.07 1.61  0.12* Nd 1.45  0.16*
HCV-RNA ()) 0.05  0.01 0.13  0.01* 0.85  0.1 1.56  0.16* Nd 1.73  0.17*
a Means  SD. b Nd, no detectable (mRNA of IFN-a was no detectable using 20 cycles of PCR amplification, which is the
number of cycles used to quantify IFN-a mRNA in Sendai virus stimulated PBMC to avoid interferences with the plateau effect.
IFN-a mRNA in unstimulated PBMC was detectable after 30 cycles of amplification).
* P < 0.05 Sendai virus stimulated vs. unstimulated PBMC.
Table 3 IFN-a subtypes in unstimulated peripheral blood mononuclear cells from healthy controls and patients with chronic
hepatitis C
Tested clones a1 a2 a4 a5 a7 a8 a10 a14 a16 a17 a21 a22
C1 12 0 0 0 8 0 1 0 0 0 0 3 0
C2 8 0 2 0 4 0 0 1 0 1 0 0 0
C3 8 2 0 0 3 0 0 0 0 0 0 2 1
C4 7 0 1 1 1 1 1 2 0 0 0 0 0
C5 12 0 1 0 8 0 0 0 0 0 0 3 0
C6 9 2 0 0 3 0 0 0 0 0 0 4 0
C7 8 0 0 0 8 0 0 0 0 0 0 0 0
C8 11 10 0 0 0 0 1 0 0 0 0 0 0
Total 75 14 4 1 35 1 3 3 0 1 0 12 1
P1 10 2 0 0 7 0 1 0 0 0 0 0 0
P2 12 2 0 0 6 2 0 0 0 0 0 2 0
P3 11 0 1 0 10 0 0 0 0 0 0 0 0
P4 10 0 0 0 8 0 0 0 0 0 0 2 0
P5 11 2 0 0 7 0 2 0 0 0 0 0 0
P6 9 0 0 0 7 1 0 0 0 0 0 1 0
P7 9 1 0 0 5 0 0 0 0 0 0 3 0
P8 11 2 0 2 4 0 0 1 0 1 0 0 1
Total 83 9 1 2 54* 3 3 1 0 1 0 8 1
C1–8 are samples from eight different normal controls. P1–8 are samples from eight different HCV-RNA (+) chronic hepatitis C
patients.
* P < 0.05 vs. healthy controls.
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HCV infection [7,36]. This report shows that the IFN system
is activated in mononuclear cells from HCV-infected patients.
Previously we have observed increased values of IFN-a and
IFN-b mRNA in PBMC from these individuals [14]. Now we
show the presence of a significant elevation of the IRF-1
and IRF-1/IRF-2 ratio in PBMC from patients with chronic
hepatitis C. IRF-1 and IRF-2 have been identified as regu-
lators of interferon and interferon-inducible genes. High
levels of IFN-inducible genes such as 2¢,5¢-oligoadenylate
synthetase and Mx proteins have been found in PBMC from
HCV infected individuals [37–39]. Similarly, high level of
expression of interferon-inducible genes have been detected
in the liver from chimpanzees during the acute phase of
hepatitis C [40]. Although IRF-1 and IRF-2 are considered to
be crucial in providing protection against several viral
infections [41,42], we found no correlation between IRF
levels and viral load or the activity of the liver disease.
Recently, a more relevant role for other members of the IRF
family, such as IRF-3 and IRF-7, has been described in viral
infections [43,44]. IRF-1 is stimulated not only by viral
infection of the cells but also by cytokines such as interferon-
gamma and IL-12 [45,46]. Since IFN-c is elevated in HCV
infection [47,48] this might contribute to the high levels of
IRF-1 seen in this disease.
To further analyse whether the interferon machinery of
PBMC responded normally to stimulation in patients with
chronic hepatitis C, we investigated the changes in IFN-a
and IRFs transcripts and the production of IFN-a protein
after in vitro stimulation of PBMC with Sendai virus. We
found that HCV infection did not result in disturbed induc-
ibility of IRFs genes nor of IFN-a production. These findings
are in contrast with those reported in patients with HBV or
HIV infections where the IFN system is impaired in PBMC
[49–50].
Very few studies have explored the role of the different
IFN-a subtypes in viral infections in humans. In 1987, Tovey
et al. using RNA blot hybridization showed that IFN-a could
be detected in the apparent absence of induction [51].
Another study performed by Greenway and coworkers
detected IFN-a in the cytoplasm of PBMC, in the absence of
viral stimulation, by immunofluorescence using polyclonal
antipeptide antisera [27]. A similar finding was reported by
Brandt et al. using the polymerase chain reaction with uni-
versal primers and with selected subtype specific primers
[26]. Lallemand et al. found that IFN-a5 was the main
subtype expressed in PBMC using PCR technique followed by
direct dideoxy sequencing [28]. The availability of automatic
sequencing after cloning the RT-PCR product, allowed us to
perform a more complete analysis of the IFN-a subtypes
expressed in normal PBMC. We have found that IFN-a5,
IFN-a1 and IFN-a21 are the main IFN-a subtypes constitu-
tively expressed in unstimulated PBMC from healthy con-
trols. The constitutive expression of IFN-a has been related to
the maintenance of HLA proteins on the cell surface [28]. In
chronically HCV-infected cells we found a significant and
selective increase of IFN-a5 subtype.
Interestingly, IFN-a5 which is the only subtype expressed
in normal liver tissue [14] and the main subtype in normal
pancreas [52], is reduced in the liver from HCV infected
patients [14]. In HCV infection the liver is the main site
of viral replication and low levels of IFN-a5 may favour
persistent HCV infection of this organ. PBMC (with higher
Table 4 IFN-a subtypes in peripheral blood mononuclear cells from normal controls (C) and patients with chronic hepatitis C
(P) before and after Sendai virus stimulation
Tested clones a1 a2 a4 a5 a7 a8 a10 a14 a16 a17 a21 a22
C1 12*-10  0–4 0–1 0–0 8–0 0–0 1–2 0–3 0–0 0–0 0–0 3–0 0–0
C2 8–12 0–6 2–3 0–0 4–1 0–0 0–2 1–0 0–0 1–0 0–0 0–0 0–0
C3 8–8 2–1 0–0 0–0 3–2 0–0 0–2 0–1 0–0 0–2 0–0 2–0 1–0
C4 7–11 0–2 1–0 1–0 1–3 1–0 1–4 2–0 0–1 0–0 0–0 0–1 0–0
C5 12–11 0–3 1–3 0–0 8–1 0–0 0–3 0–0 0–0 0–0 0–0 3–1 0–0
Total 47–52 2–16 4–7 1–0 24–7 1–0 2–13à 3–4 0–1 1–2 0–0 8–2 1–0
P1 10–12 2–6 0–1 0–0 7–2 0–1 1–2 0–0 0–0 0–0 0–0 0–0 0–0
P2 12–9 2–1 0–2 0–0 6–1 2–0 0–3 0–0 0–0 0–1 0–1 2–0 0–0
P3 11–12 0–2 1–2 0–0 10–0 0–2 0–4 0–1 0–0 0–0 0–0 0–1 0–0
P4 10–12 0–6 0–2 0–0 8–1 0–0 0–3 0–0 0–0 0–0 0–0 2–0 0–0
P5 11–12 2–5 0–0 0–0 7–0 0–0 2–6 0–1 0–0 0–0 0–0 0–0 0–0
Total 54–57 6–20 1–7 0–0 38–4à 2–3 3–18à 0–2 0–0 0–1 0–1 4–1 0–0
C1–5 are samples from five different normal controls. P1–5 are samples from five different HCV-RNA (+) chronic hepatitis C
patients.
* Number of cDNA clones before Sendai virus stimulation.  Number of cDNA clones after Sendai virus stimulation. àP < 0.05
Sendai virus stimulated vs. unstimulated.
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levels of IFN-a5 transcripts) may act as a reservoir for HCV
but these cells allow HCV replication at levels considerably
lower than in the liver [2]. Further studies using quantitative
PCR specific for IFN-a5 are needed to determine whether the
levels of this IFN-a subtype can correlate with the replicative
activity of the virus.
In contrast to what happens in natural HCV infection,
in vitro infection with Sendai virus selectively upregulates
IFN-a8 in both normal subjects and HCV infected patients
cells. It has been reported that monocytes and the so called
‘natural IFN-producing cells’ (NIPC), which are thought to
be dendritic cells, are the two major IFN-a producing cells in
PBMC [53]. IFN-a production in response to Sendai virus
occurs predominantly in monocytes, whereas most envel-
oped viruses stimulate NIPC [54]. IFN-a produced by
virus-activated IFN-producing cells contributes to the
differentiation of these cells into dendritic cells [55]. If the
different IFN subtype expression we detected reflects selective
IFN-a production by different PBMC subpopulations and
whether it has a role in the altered function of dendritic cells
in patients with HCV [56] needs to be studied.
In summary, the interferon system is activated in PBMC
from subjects with chronic HCV infection. The response of
PBMC to in vitro stimulation with Sendai virus is preserved
in chronic hepatitis C. While Sendai virus induces prefer-
entially IFN-a8 in both patients and healthy controls, HCV
infection of PBMC is associated with IFN-a5 subtype
expression. The role of IFN-a5 in the control of HCV infection
should be investigated.
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